Thyroid eye disease is common, yet poorly understood. Clarification of the pathogenesis of thyroid eye disease should provide a rational therapeutic approach. This article provides a review of current pathogenic theories for the condition and of the medical management based on those theories.

Bartley GB: The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994;92:477–588.
Werner SC: Modification of the classification of the eye changes of Graves’ disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 1977;44:203–204.
Werner SC: Classification of thyroid disease: report of the Committee on Nomenclature. The American Thyroid Association. J Clin Endocrinol Metab 1969;29:860–862.
Molnár I: The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves’ disease during methimazole therapy. Autoimmunity 2007;40:31–37.
Weetman AP: Hyperthyroidism and Graves’ disease; in Besser GM, Thorner MO (eds): Comprehensive Clinical Endocrinology, ed 3. Edinburgh, Mosby, 2002, pp 165–180.
Durairaj VD: Clinical perspectives of thyroid eye disease. Am J Med 2006;119:1027–1028.
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L: Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 1997;47:9–14.
Gerding MN, Prummel MF, Wiersinga WM: Assessment of disease activity in Graves’ ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 2000;52:641–646.
Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA: Chronology of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:426–443.
Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE: Thyrotropin receptor expression in Graves’ orbital adipose-connective tissues: potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab 1998;83:998–1002.
Khoo TK, Bahn RS: Pathogenesis of Graves’ ophthalmopathy: the role of autoantibodies. Thyroid 2007;17:1013–1018.
Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y: IL-23R is a major susceptibility gene for Graves’ ophthalmopathy: the IL-23/Th17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 2007;93:1077–1081.
Lacka K, Manuszewska E, Korczowska I, Lacki JK: The effect of methylprednisolone pulse treatment on cytokine network in Graves’ ophthalmopathy. Curr Eye Res 2007;32:291–297.
Konuk EB, Konuk O, Misirlioglu M, Menevse A, Unal M: Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves’ ophthalmopathy patients. Eur J Endocrinol 2006;155:681–685.
Quadbeck B, Stucke M, Eckstein AK, Heise DJ, Mann K, Gieseler RK: Dysregulation of TNF/TNFR superfamily members: a systemic link between intra- and extrathyroidal manifestations in Graves’ disease. Scand J Immunol 2006;64:523–530.
Wiersinga WM: Management of Graves’ ophthalmopathy. Nat Clin Pract Endocrinol Metab 2007;3:396–404.
Kahaly GJ, Pitz S, Hommel G, Dittmar M: Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 2005;90:5234–5240.
Zoumalan CI, Cockerham KP, Turbin RE, Volpe NJ, Kazim M, Douglas RS, Feldon SE: Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuroophthalmol 2007;27:205–214.
Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN: Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol 2002;61:7–12.
Vondrichova T, de Capretz A, Parikh H, Frenander C, Asman P, Aberg M, Groop L, Hallengren B, Lantz M: COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves’ ophthalmopathy. Thyroid 2007;17:511–517.
Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Hegedüs L: B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves’ ophthalmopathy, the latest addition to an expanding family. Expert Opin Biol Ther 2007;7:1061–1078.
El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L: B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J Clin Endocrinol Metab 2007;92:1769–1772.
Salvi M, Vannucchi G, Campi I, Currò N, Beck-Peccoz P: New immunomodulators in the treatment of Graves’ ophthalmopathy. Ann Endocrinol 2008;69:153–156.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.